United Therapeutics Expands Immune Therapy Pipeline With Thymmune

United Therapeutics Corp. (NASDAQ: UTHR ) said Thursday it has acquired privately held Thymmune Therapeutics. Thymmune is a preclinical biotechnology company developing regenerative thymic cell therapies designed to restore immune function and improve transplant outcomes. Read Also: FDA Approval Positions United Therapeutics To Broaden Access To Donor Lungs Acquisition Includes Milestone-Based Payments Under the agreement, United Therapeutics will pay $140 million in cash, subject to certain post-closing adjustments. United Therapeutics reported cash and cash equivalents of $1.28 billion as of March 31, 2026. Former Thymmune shareholders are also eligible for up to $160 million in additional earn-out payments tied to clinical and regulatory milestones through the end of 2031. Deal Brings Preclinical Thymic Cell Therapy Platform Thymmune is a preclinical-stage biotechnology company dev...